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Natural products often unite structure and 
function in unforeseen ways. Such facets have 
long driven total synthesis and drug discovery 
campaigns. The challenge for the chemist is to 
orchestrate a sequence of synthetic methods into 
a workable, clever strategy. For the biologist, it is 
to reveal and cleverly harness drug targets in new, 
therapeutic ways. In our group, we aim to tackle 
such challenges by advancing methods and 
strategies in organic and medicinal chemistry. 
 
Synthetically speaking, the complex 
multifunctionalized environments of natural 
products typically limit the effectiveness of a 
chosen method to achieve a desired reaction. 
Carbanions, organometalics and countercations, 
for example, will often experience competing 
interactions outside their designed or known roles. 
In a total synthesis or a chemical biology setting, 
each chosen method may be scrutinized on the 
basis of several interrelated criteria. These may 
include: chemo-, regio-, stereoselectivity; 
substrate-to-substrate, reagent stoichiometry; 
practicality, efficiency, scalability; solvent, 
reagent, time economy; atom, redox, protecting-
group, step economy; substrate scope, versatility, 
diversity; steric, electronic, functional-group 
tolerance; biosynthetic, biomimetic, bio-
orthogonal nature; budget, energy, ecology costs. 
 
Such ideals need to be sensibly balanced within a 
multistep synthesis; whether a key building block 
is being constructed or a key coupling step is 
being optimized (or even devised). Herein, we 
present key methods and strategies that were 
advanced en route to uncovering the chemistry 
and biology of the (1) laetirobins1, (2) lipstatins2, 
(3) platensimycins3, and (4) bielschowskysin4. 
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